Sickle cell drug underused, experts agree

By Maggie Fox, Health and Science Editor

WASHINGTON (Reuters) - An inexpensive cancer pill that can relieve the painful symptoms of sickle cell disease is used far too little and patients are needlessly suffering as a result, a panel of U.S. experts agreed on Wednesday.

They said as many as half of all patients with sickle cell disease could be helped by hydroxyurea, but no more than 3 percent to 5 percent are likely using the drug.

A shortage of doctors specializing in sickle cell disease, along with a batch of rumors about the drug's safety, worsens the problem, the National Institutes of Health consensus panel agreed.

"One of the first problems is we don't even know how many people have sickle cell disease," Dr. Otis Brawley, who chaired the meeting at the NIH, said in a telephone interview.

"You can find data that says the number of sickle cell patients is between 50,000 and 75,000 and you can find other papers that say it is between 50,000 and 120,000," added Brawley, a professor of hematology, oncology and epidemiology at Emory University in Atlanta and chief medical officer of the American Cancer Society.

Hydroxyurea, which is now available generically, was approved by the U.S. Food and Drug Administration in 1998 for use in adults with sickle cell anemia, a disease caused by abnormally shaped red blood cells.

The cells die early, or get stuck in blood vessels, blocking blood flow and causing pain and organ damage. Hydroxyurea can stop the severe pain and prevent the need for blood transfusions.

"The compelling benefits of hydroxyurea warrant increased adoption of this drug as a front-line therapy in adults with sickle cell disease," Brawley said.